Product Availability Update

Promega Manufacturing and Delivery Systems continue to be fully operational during the COVID-19 outbreak. Our teams are in regular contact with suppliers and distributors worldwide and are taking all steps necessary to address both demands for diagnostic tools and reliable delivery of all products as quickly as possible. Learn more

Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

A Murine ADCC Reporter Assay for Vaccine and Antibody Drug Preclinical Development

Part # PS351

Abstract

Alieen Pagiuo, Teresa Surowy and Frank Fan
Promega Corporation, 2800 Woods Hollow Road, Madison, WI 53711, USA

In preclinical studies in mice, assessment of antibody dependent cell mediated cytotoxicity (ADCC) of a vaccine or antibody drug candidate is essential. Traditional murine ADCC assays are arduous and highly variable, typically requiring the isolation, cell culture, and in some cases differentiation of bone marrow monocytes/macrophages or NK cells.

In an effort to develop a less variable mouse ADCC bioassay with improved performance and workflow, we utilized bioluminescent reporter based technology. Specifically, we developed a bioassay that exhibits FcγRIV mediated ADCC pathway activation in response to native mouse antibodies, chimeric, humanized and human antibodies with the expected IgG subclass specificity. The bioassay is specific and can appropriately discriminate between antibodies of different IgG subclasses. The bioassay cells are provided in thaw and use format, are compatible with both adherent and suspended target cells, and together with an optimized protocol provide low assay variability and a more streamlined workflow compared to traditional mouse ADCC bioassays.

Printed in USA.